Bolt Biotherapeutics, Inc. cotiza a 4.24 USD y tiene una capitalización bursátil de $8M. En los últimos 12 meses ha facturado $5M con un margen de flujo de caja libre del -518.8%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junct…
| Periodo | 2026-03 | 2025-11 | 2025-08 | 2025-08 |
|---|---|---|---|---|
| Real | $-2.98 | $-3.72 | $-4.46 | — |
| Estimado | $-5.52 | $-5.39 | $-6.27 | $-6.27 |
| Sorpresa | +46.0% | +31.0% | +28.9% | — |
| Métrica | BOLT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -469.3% | -38.6% | -430.7% |
| Net Margin | -433.7% | -33.6% | -400.2% |
| FCF Margin | -518.8% | -13.9% | -504.9% |
| ROE | -125.9% | -40.4% | -85.5% |
| ROA | -58.8% | -32.0% | -26.8% |
| Current Ratio | 3.59 | 2.84 | +0.75 |
| Debt / Equity | — | 0.28 | — |